Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBridge Biosciences (NBP) Non-Current Deferred Tax Liability (2018 - 2022)

NovaBridge Biosciences (NBP) has disclosed Non-Current Deferred Tax Liability for 3 consecutive years, with $2.5 million as the latest value for Q4 2022.

  • Quarterly Non-Current Deferred Tax Liability fell 10.69% to $2.5 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $2.5 million through Dec 2022, down 10.69% year-over-year, with the annual reading at $2.6 million for FY2022, 7.93% down from the prior year.
  • Non-Current Deferred Tax Liability for Q4 2022 was $2.5 million at NovaBridge Biosciences, down from $2.8 million in the prior quarter.
  • The five-year high for Non-Current Deferred Tax Liability was $5.4 million in Q4 2018, with the low at $2.5 million in Q4 2022.
  • Average Non-Current Deferred Tax Liability over 3 years is $3.6 million, with a median of $2.8 million recorded in 2021.
  • Peak annual rise in Non-Current Deferred Tax Liability hit 10.69% in 2022, while the deepest fall reached 10.69% in 2022.
  • Over 3 years, Non-Current Deferred Tax Liability stood at $5.4 million in 2018, then plummeted by 47.83% to $2.8 million in 2021, then fell by 10.69% to $2.5 million in 2022.
  • According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods came in at $2.5 million, $2.8 million, and $5.4 million for Q4 2022, Q4 2021, and Q4 2018 respectively.